Emcure Pharmaceuticals reported a strong financial performance for the second quarter of FY24, driving a positive market response as its shares edged higher. The company’s profit after tax (PAT) surged by 38.2 per cent year-on-year to Rs 201.5 crore, up from Rs 145.8 crore in the same period last year, signalling robust growth across its core business segments.

Revenue and EBITDA growth
Emcure’s revenue rose by 20.4 percent to Rs 2,002 crore in Q2 FY24, compared to Rs 1,663 crore in Q2 FY23, reflecting solid demand across its product portfolio. The growth was primarily driven by strong sales in the domestic and international markets, bolstered by new product launches and increased market penetration.

The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) grew by 15.8 percent year-on-year, reaching Rs 380.9 crore, up from Rs 329 crore last year. Despite a strong increase in EBITDA, the margin contracted slightly by 80 basis points to 19 percent from 19.8 percent in the previous year. The dip in margins was attributed to increased input costs and a higher expenditure on R&D initiatives, aimed at bolstering its future product pipeline.

Outlook remains positive despite margin pressure
While Emcure’s operating margin saw a slight decline, the overall financial performance indicates a healthy growth trajectory. Analysts believe that the strong revenue growth and PAT increase reflect the company’s resilience amid challenging macroeconomic conditions. The company’s focus on expanding its product range and strengthening its market position is expected to continue supporting revenue growth. However, margin pressures from elevated input costs may remain a concern in the near term.

Going forward, Emcure’s strategic initiatives in R&D and market expansion are likely to play a crucial role in sustaining its growth momentum, making the company well-positioned to capitalize on new market opportunities.

Article Source : zeebiz Website